NCT00852839 - A Safety and Efficacy Study of 552-02 in Subjects With Dry Mouth Associated With Sjogren's Syndrome | Biotech Hunter

Enrollment

140

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

October 31, 2009

Study Completion Date

November 30, 2009

Conditions

Dry Mouth Associated With Sjogren's SyndromeXerostomia

Interventions

DRUG

Placebo

Placebo to match oromucosal formulation of 552-02

DRUG

552-02

The oromucosal formulation of 552-02 contains 552-02 (25 μg/mL), surfactant, flavoring agents, a humectant, and preservatives.

Trial Locations (15)

11501

Winthrop University Hospital, Mineola

14518

AAIR Research Center, Rochester

16635

Altoona Center for Clinical Research, Duncansville

19104

Penn Rheumatology Associates, Philadelphia

20902

The Center for Rheumatology and Bone Research, Wheaton

26232

Carolinas Medical Center, Charlotte

32610

University of Florida College of Dentristy, Gainesville

37909

Rheumatology Consultants, Knoxville

46202

Indiana School of Dentristy, Indianapolis

73104

Oklahoma University, Oklahoma City

75246

Arthritis Centers of Texas, Dallas

78229

Univ. of Texas Health Science Center, San Antonio

99204

Arthritis Northwest, Spokane

06611

New England Research Associates, LLC, Trumbull

02111

Tufts University School of Dental Medicine, Boston